Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: International IP
-
By Juan Serrano — The Federal Commission for Protection Against Sanitary Risks (COFEPRIS) is the Mexican equivalent of the U.S. Food and Drug Administration (FDA). For the past three years this Commission was headed by Miguel Angel Toscano, who had previously held a position at the Ministry of Economy. Mr. Toscano's exit from COFEPRIS has…
-
By Donald Zuhn — Last week, the World Intellectual Property Organization (WIPO) announced that International patent filings under the Patent Cooperation Treaty (PCT) rose from 155,398 in 2009 to 162,900 in 2010 — an increase of 4.8%. While the United States ranked first in filings with 44,855 applications, this still marked a 1.7% decline from…
-
By Donald Zuhn — On February 4, the U.S. Patent and Trademark Office and European Patent Office announced that the two offices had reached agreement on the principles of a new joint patent classification system known as the Cooperative Patent Classification (CPC). The desire to develop a joint classification system was first announced last fall…
-
By Donald Zuhn — Last month, the European Patent Office (EPO) announced that in some circumstances, applicants would be exempted from filing a copy of search results under amended Rule 141(1) EPC. Prior to the EPO's announcement, the new rule would have required applicants to provide a copy of the results of any search that…
-
By Donald Zuhn — Reflecting upon the events of the past twelve months, Patent Docs presents its fourth annual list of top biotech/pharma patent stories. For 2010, we identified a dozen stories that we covered on Patent Docs last year that we believe had (or are likely to have) the greatest impact on biotech/pharma patent…
-
By James DeGiulio — Earlier this year, we reported that the European Union was on the verge of adopting a new patent system that would create a unified patent and patent court (see "Europe Takes Step Closer to Single EU Patent and Patent Court"). However, the 30-year push to unify the European Union patent system…
-
By Catherine Lemay — Canada's Data Protection regime was upheld by the Federal Court of Appeal on December 9, 2010 (see Apotex Inc. v. Canada (Health), 2010 FCA 334). In a unanimous decision penned by Justice Nadon, the Court found the regime was a proper delegation by the Canadian Parliament to the Governor in Council…
-
By James DeGiulio — On November 23, the European Medicines Agency (EMA) published guidelines for biosimilar monoclonal antibodies (mAb). Earlier this week, we reported on the clinical and non-clinical study portion of the guidelines (see "EMA Publishes Guidelines for Biosimilar Antibodies – Part I"). The EMA released a second set of guidelines along that directly…
-
By James DeGiulio — On November 23, the European Medicines Agency (EMA) finally published its guidelines for biosimilar monoclonal antibodies (mAb). The two-part guidelines are now subject to public consultation until May 31, 2011, after which the guidelines are to be finalized. At first glance, it appears that the EMA has relaxed several classic requirements…
-
By James DeGiulio — On January 1, 2011, all direct European patent applications and European national phase applications will be subject to new EPC Rules 141 and Rule 70b, which modify the requirements for supplying search results on priority applications. In December 2009, the European Patent Office (EPO) announced in the Official Journal the amendment…
Patent Docs 